3TOG image
Entry Detail
PDB ID:
3TOG
Title:
HIV-1 Protease - Epoxydic Inhibitor Complex (pH 9 - Monoclinic Crystal form P21)
Biological Source:
PDB Version:
Deposition Date:
2011-09-05
Release Date:
2012-08-15
Method Details:
Experimental Method:
Resolution:
1.24 Å
R-Value Free:
0.26
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Gag-Pol polyprotein
Mutations:Q507K L533I L563I C567A C595A
Chain IDs:A, B, C, D
Chain Length:99
Number of Molecules:4
Biological Source:Human immunodeficiency virus type 1 (BRU ISOLATE)
Peptide-like Molecules
PRD_001019
Primary Citation
Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.
Molecules 21 ? ? (2016)
PMID: 27809253 DOI: 10.3390/molecules21111458

Abstact

Protease inhibitors are key components in the chemotherapy of HIV infection. However, the appearance of viral mutants routinely compromises their clinical efficacy, creating a constant need for new and more potent inhibitors. Recently, a new class of epoxide-based inhibitors of HIV-1 protease was investigated and the configuration of the epoxide carbons was demonstrated to play a crucial role in determining the binding affinity. Here we report the comparison between three crystal structures at near-atomic resolution of HIV-1 protease in complex with the epoxide-based inhibitor, revealing an in-situ epoxide ring opening triggered by a pH change in the mother solution of the crystal. Increased pH in the crystal allows a stereospecific nucleophile attack of an ammonia molecule onto an epoxide carbon, with formation of a new inhibitor containing amino-alcohol functions. The described experiments open a pathway for the development of new stereospecific protease inhibitors from a reactive lead compound.

Legend

Protein

Chemical

Disease

Primary Citation of related structures